Pulnovo PADN cuts clinical worsening by 51% in 264-patient PH-LHD trial
Pulnovo’s randomized PADN-HF-PH study found a 51% reduction in clinical worsening with pulmonary artery denervation plus medical therapy, with results published in NEJM.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Can denervating the pulmonary artery reduce heart-failure events? Pulnovo begins pivotal US test
Pulnovo has treated the first two US patients in PULSE-LHD, a randomized 750-patient IDE study testing whether pulmonary artery denervation can reduce major heart-failure events in combined pre- and post-capillary pulmonary hypertension.
Medical Devices & Diagnostics
Medtronic backs Pulnovo Medical in $100m round to expand PADN in pulmonary hypertension
Pulnovo Medical raised $100 million with Medtronic backing. Read what it means for PADN, pulmonary hypertension, heart failure, and device markets.